Author: Ravi Shankar

CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma. The meeting is scheduled for early January 2027.

At the meeting, NeOnc intends to review the NEO100 nonclinical and clinical data package, including results from the completed Phase 2a portion of the NEO100-01 trial, and to seek the FDA’s feedback on whether these data could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval under section 506(c) of the Federal Food, Drug, and Cosmetic Act. The Company also intends to seek the FDA’s agreement on the design of NEO100-012, a multicenter, randomized, controlled Phase 3 trial comparing intranasal NEO100 with investigator’s-choice standard-of-care chemotherapy in patients with recurrent or progressive IDH-mutant grade 4 astrocytoma, with overall survival as the primary endpoint. The Phase 3 is intended to serve as the registrational and confirmatory trial for NEO100: under the accelerated approval framework, the Company would expect the trial to be underway, with enrollment ongoing, at the time of any NDA submission, and its final overall survival analysis to verify clinical benefit and support conversion to traditional approval. Discussion topics will also include the adequacy of the existing nonclinical safety package, the scientific bridge from published perillyl alcohol data to intranasal NEO100, and the eligibility of NEO100 for Breakthrough Therapy designation.

“We believe the safety and efficacy results from the Phase 2a portion of NEO100-01 in recurrent IDH-mutant grade 4 astrocytoma, together with our nonclinical data, provide a sound basis for discussing a potential accelerated approval pathway with the FDA and for aligning with the agency on the design of our Phase 3 confirmatory trial,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “We look forward to exploring this approach with the agency as we work to bring NEO100 to patients who urgently need new options.”

On August 12, 2026, NeOnc reported topline results from the Phase 2a portion of NEO100-01. In the analysis of the interim database lock (data cutoff June 24, 2026), the six-month progression-free survival (PFS-6) rate was 48.9% (95% CI: 26.3–68.1) by RANO 2.0 criteria, exceeding the protocol-defined benchmark of 20% for standard of care (one-sided p = 0.0047). Median overall survival was 26.1 months (95% CI: 8.5–27.1), and estimated overall survival was 86.7% at six months, 61.5% at 12 months and 54.7% at 18 and 24 months, with five patients remaining on treatment at the interim database lock. MRI assessments were performed by independent central review. No treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events or discontinuations for treatment-related adverse events were reported; treatment-related adverse events were Grade 1–2 and predominantly local nasal or upper-airway effects.

NeOnc expects to provide an update following receipt and review of the FDA’s official meeting minutes.

About Accelerated Approval

The FDA’s Accelerated Approval program allows drugs for serious conditions that fill an unmet medical need to be approved based on an effect on a surrogate endpoint or an intermediate clinical endpoint that is reasonably likely to predict clinical benefit, rather than waiting for a direct measure of benefit such as longer survival. Companies whose drugs receive accelerated approval are required to conduct confirmatory trials to verify the anticipated clinical benefit, which may support conversion to traditional approval. Under amendments to the Federal Food, Drug, and Cosmetic Act enacted in 2022, the FDA may require that a confirmatory trial be underway before accelerated approval is granted.

About the NEO100-01 Study

NEO100-01 is an open-label, multi-center Phase 1/2a study of intranasal NEO100 in patients with radiographically confirmed progression of, or recurrence of, primary or secondary Grade IV glioma or Grade III astrocytoma harboring an IDH1 mutation. The Phase 2a portion treated 28 patients at the recommended Phase 2 dose of 1,152 mg/day, of whom 24 patients with IDH1-mutant tumors (21 with grade 4 disease) constitute the efficacy population; enrollment is complete and five patients remained on treatment at the interim database lock. The primary endpoint is the progression-free survival rate at six months.

About NEO100

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established. NEO100 has received Fast Track designation from the FDA for the treatment of high-grade glioma and Orphan Drug designation for the treatment of gliomas.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated timing of the FDA meeting, the topics to be discussed, a potential accelerated approval pathway, a potential 505(b)(2) New Drug Application, the design, initiation, enrollment and timing of the planned NEO100 Phase 3 trial and whether it will be underway at the time of any NDA submission or will verify clinical benefit, the Company’s clinical development programs and the clinical potential of NEO100. Forward-looking statements in this release also include statements regarding the clinical potential of NEO212. These statements reflect current expectations and involve risks and uncertainties. NEO100 is investigational and has not been approved by any regulatory authority; future studies may not demonstrate safety or efficacy; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. The scheduling of the FDA meeting does not establish FDA agreement on a development plan, an accelerated approval pathway or eventual approval of NEO100. NEO212 is also investigational and has not been approved by any regulatory authority. The NEO100 Phase 2a study was a single-arm, open-label study that was not powered as a confirmatory trial. The Phase 2a results described in this release are from an interim database lock and may change at the final analysis; comparisons to historical benchmarks are not based on a randomized comparison. The FDA may not agree that NEO100 Phase 3 as designed is an adequate confirmatory trial, may require changes to its design or enrollment status before any accelerated approval, and the trial may not confirm clinical benefit. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release. The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

This press release was published by a CLEAR® Verified individual.

LightSolver to present its Boeing corrosion-simulation work and join Birds of a Feather (BoF) session on analog computing at the supercomputing conference in Chicago

Rehovot, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) — CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd. (“LightSolver”), a pioneer of pure photonic computing and developer of the Laser Processing Unit (LPU)™, will unveil the LPU capabilities in a first public demonstration at SC26, the International Conference for High Performance Computing, taking place November 15-20, 2026 in Chicago. The demonstration will be presented at LightSolver’s booth #5102 during the exhibition, November 16-19.

The LPU is a photonic computer designed to process and solve mathematical problems using light itself, through interacting laser beams, rather than conventional electronic computation. In this first public demonstration of an all-optical computer, LightSolver will showcase live how the LPU solves real mathematical and computational problems – including systems of linear equations, differential equations, and complex optimization problems – using only interacting light.

The LPU is designed to operate alongside conventional GPUs, with the potential to significantly accelerate certain computationally intensive workloads while offering the potential for reductions in energy consumption. These capabilities build on previously published, peer-reviewed research conducted in collaboration with the High-Performance Computing Center Stuttgart (HLRS), as well as ongoing paid collaboration programs with leading industrial partners, including Boeing and others.

Boeing Corrosion Simulation at the Exhibitor Forum
LightSolver will present its work with Boeing on PDE-based corrosion simulation at the SC26 Exhibitor Forum. The presentation will set out the engineering problem and present comparative benchmark results against existing solvers. The work is part of a paid, multi-year development program with Boeing, announced in April 2026.

Analog Computing with the HPC Research Community
LightSolver will also take part in a Birds of a Feather session informed by the U.S. Department of Energy report “Analog Computing for Science: From Emerging Technologies to a Shared Research Agenda,” alongside researchers from HLRS, Pacific Northwest National Laboratory (PNNL), TU Dresden and other institutions. Dr. Talya Vaknin, Head of Research at LightSolver, will present the company’s perspective on the advantages of keeping most of the computation in the optical domain.

“The first public demonstration of an entirely new type of computer — one that uses light itself to perform computation — marks a major milestone for LightSolver as we work to move from a working prototype toward a commercial product,” said Dr. Ruti Ben Shlomi, Co-Founder and CEO of LightSolver. “It is an exciting moment for our company and everyone involved in building this new computing paradigm. We see this as an important step toward our long-term vision of photonic computing in data centers, which we believe has the potential to perform computational workloads at significantly higher speeds while reducing energy consumption. And there is no better place to showcase this technology than at a leading supercomputing event, where the world’s experts, researchers, industry leaders, and innovators in high-performance computing come together. It is the ideal stage to introduce this new computing paradigm to the community that will help shape the future of computing. We believe that computing with light has the potential to fundamentally transform the future of computing infrastructure.”

Investors and analysts interested in meeting LightSolver management in Chicago during SC26, or in New York and the San Francisco Bay Area, may contact investors@lightsolver.com to arrange a meeting.

Subject to shareholder approval, CollPlant intends to change its name to OptiPhi Computing Ltd. and, subject to Nasdaq confirmation, its Nasdaq ticker symbol from “CLGN” to “OPHI.” For additional details, please see CollPlant’s announcement dated November 4, 2026.

About CollPlant
CollPlant (Nasdaq: CLGN) is an innovative technology company operating at the intersection of deep-tech photonic computing and advanced biotechnology. Through its subsidiary LightSolver, CollPlant is advancing the development of proprietary all-optical laser-based computing architectures designed to resolve the world’s most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing. CollPlant also retains its proprietary plant-derived recombinant human collagen (rhCollagen) and bio-ink assets, for 3D bioprinting of tissues and organs and medical aesthetics. For more information about CollPlant, visit www.collplant.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the planned demonstration of LightSolver’s LPU and its presentations at SC26; the extent to which results shown on current LPU hardware or in benchmarks may be replicated at larger scale and in real-world workloads; the anticipated performance, capabilities, energy efficiency and applications of the LPU; LightSolver’s development roadmap and its efforts to move toward a commercial product; LightSolver’s long-term vision for photonic computing in data centers; LightSolver’s collaboration programs, including with Boeing; the proposed change of CollPlant’s name and Nasdaq ticker symbol; and the future prospects, business plans and growth strategies of CollPlant and LightSolver. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “continue,” “potential,” “vision” and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that the LPU does not perform as expected in live demonstrations or that benchmark results are not representative of performance in real-world or larger-scale applications; LightSolver’s ability to scale its technology from prototype to a commercial product; LightSolver’s dependence on collaboration partners, including Boeing, and the risk that such programs are delayed, modified or terminated; the risk that shareholder approval or Nasdaq confirmation of the proposed name and ticker symbol change is not obtained; obligations and restrictions under the Israeli Encouragement of Research, Development and Technological Innovation in the Industry Law, 5744-1984, including royalty payment obligations and restrictions on the transfer of IIA-funded know-how and manufacturing outside of Israel; risks associated with integrating LightSolver’s business, operations and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant’s ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investors Contact
CollPlant Biotechnologies
investors@lightsolver.com

Arx Investor Relations
North American Equities Desk
collplant@arxhq.com

Revenue of $18.1 million, up 4.5% year over year; first-half operating cash flow of $4.7 million
Reaffirms fiscal year 2027 financial guidance

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — Aeries Technology, Inc. (Nasdaq: AERT), a global provider of AI transformation and enterprise operations solutions, today announced financial results for the second quarter of fiscal 2027, ended September 30, 2026.

Second-quarter revenue increased 4.5% year over year to $18.1 million, while net income increased to $1.3 million from $0.6 million in the prior-year quarter.

For the first half of fiscal 2027, revenue increased 23% year over year to $40.1 million, including $2.7 million associated with a previously disclosed customer buyout recognized in the first quarter. Net income increased to $3.6 million from $2.3 million, and Adjusted EBITDA increased 72% to $6.2 million from $3.6 million, with an Adjusted EBITDA margin of 15.4% compared with 11.0% in the prior-year period. Operating cash flow for the first half increased approximately 98% year over year to $4.7 million.

Second Quarter Fiscal 2027 Financial Highlights

• Revenue: $18.1 million, an increase of 4.5% from $17.3 million in the prior-year quarter.
• Net income: $1.3 million, compared with $0.6 million in the prior-year quarter.
• Adjusted EBITDA: $2.1 million, compared with $2.6 million in the prior-year quarter, representing margins of 11.6% and 14.7%, respectively.

First Half Fiscal 2027 Financial Highlights

• Revenue: $40.1 million*, an increase of 23% from $32.7 million in the prior-year period.
• Net income: $3.6 million*, compared with $2.3 million in the prior-year period.
• Adjusted EBITDA: $6.2 million*, an increase of 72% from $3.6 million in the prior-year period, representing margins of 15.4% and 11.0%, respectively.
• Operating cash flow: $4.7 million, an increase of approximately 98% from $2.4 million in the prior-year period.

_{* First-half results include $2.7 million associated with a previously disclosed customer buyout recognized in the first quarter.}

Management Commentary

“Our second-quarter results reflect continued progress in executing our operating priorities, with year-over-year revenue growth, improved net income, and healthy cash generation during the first half of fiscal 2027,” said Ajay Khare, Chief Executive Officer of Aeries Technology. “We remain focused on serving our clients, maintaining financial discipline, and positioning the business for sustainable growth.”

Business Update

During the quarter, Aeries continued to advance its AI transformation and enterprise operations offerings, including the introduction of AxAI, its agentic AI solution offering, in September 2026. The Company continues to develop its AI capabilities alongside its AeriesOne enterprise operations platform to support evolving client requirements.

Financial Outlook

Aeries reaffirmed its previously announced fiscal year 2027 financial guidance:

• Revenue: $80 million to $84 million
• Adjusted EBITDA: $10 million to $12 million

About Aeries Technology

Aeries Technology, Inc. (Nasdaq: AERT) helps organizations worldwide create enterprise value through AI transformation and managed operations. Through its portfolio, including AxAI and AeriesOne, Aeries combines AI innovation, engineering expertise, business process knowledge, and managed global operations to help customers transform business functions and improve operational performance.

Founded in 2012, Aeries serves global enterprises through delivery centers in India and Mexico. For more information, visit www.aeriestechnology.com.

Conference Call Details

The Company will host a conference call to discuss its financial results on Thursday, November 12, 2026, at 8 AM ET. The call will be accessible by telephone at 1-800-715-9871 (toll-free, US and Canada) or 1-646-307-1963 (US and international), Conference ID 6494642. The call transcript will also be available on the Company’s investor relations website at https://ir.aeriestechnology.com/

Non-GAAP Financial Measures

The Company uses non-GAAP financial information and believes it is useful to investors because it provides additional information to facilitate comparisons of historical operating results, identify trends in its underlying operating results, and provide additional insight and transparency into how it evaluates the business. The Company uses non-GAAP financial measures to budget, make operating and strategic decisions, and evaluate its performance. The Company has detailed the non-GAAP adjustments it makes in the non-GAAP definitions below. These adjustments generally fall within the categories of non-cash items. The Company believes the non-GAAP measures presented herein should always be considered alongside, and not as a substitute for or superior to, the related GAAP financial measures. In addition, similarly titled items used by other companies may not be comparable due to variations in how they are calculated and how terms are defined. For further information, see “Reconciliation of Non-GAAP Financial Measures” below, including the reconciliations of these non-GAAP measures to their most directly comparable GAAP financial measures. The Company defines Adjusted EBITDA as net income (loss) before interest, income taxes, depreciation, and amortization, further adjusted to exclude stock-based compensation, M&A transaction-related costs, and changes in the fair value of derivative liabilities. Adjusted EBITDA is a key performance indicator the Company uses in evaluating its operating performance and in making financial, operating, and planning decisions. The Company believes this measure is useful to investors in evaluating Aeries’ operating performance, as such information is used by the Company’s management for internal reporting and planning procedures, including aspects of its consolidated operating budget and capital expenditures. Adjusted EBITDA has some limitations in that it does not reflect: (i) cash expenditures or future requirements for capital expenditures or contractual commitments; (ii) foreign exchange gains or losses; (iii) changes in, or cash requirements for, working capital; (iv) significant interest expense or the cash requirements necessary to service interest or principal payments on the Company’s outstanding debt; (v) payments made or future requirements for income taxes; (vi) cash requirements for future replacement or payment of depreciated or amortized assets; (vii) stock-based compensation costs; and (viii) changes in the fair value of derivative liabilities. The Company defines Adjusted EBITDA Margin as Adjusted EBITDA divided by Revenue. The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the Company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the Company’s results calculated in accordance with GAAP.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “should”, “would”, “will”, “understand” and similar words are intended to identify forward-looking statements. These forward-looking statements include but are not limited to statements regarding our future operating results, outlook, guidance and financial position, our business strategy and plans, our objectives for future operations, potential acquisitions and macroeconomic trends. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Aeries and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to: our ability to continue as a going concern; our ability to retain and expand our client base; changes in the business, market, financial, political and legal conditions in India, Singapore, the United States, Mexico, the Cayman Islands and other countries, including developments with respect to inflation, interest rates and the global supply chain, including with respect to economic and geopolitical uncertainty in many markets around the world, the potential of decelerating global economic growth and increased volatility in foreign currency exchange rates; the potential for our business development efforts to maximize our potential value; the ability to maintain the listing of our Class A ordinary shares and our public warrants on Nasdaq, and the potential liquidity and trading of our securities; changes in applicable laws or regulations and other regulatory developments in the United States, India, Singapore, Mexico, the Cayman Islands and other countries; our success in retaining or recruiting, or changes required in, our officers, key employees or directors; our financial performance; our ability to make acquisitions, divestments or form joint ventures or otherwise make investments and the ability to successfully complete such transactions and integrate with our business; the period over which we anticipate our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements; geopolitical instability, armed conflicts, trade restrictions, tariffs and other international events that may adversely affect global economic conditions, customer spending and business operations, and any restrictive actions that have been or may be taken by the U.S. and/or other countries in response thereto, such as sanctions or export controls; risks related to cybersecurity and data privacy; the impact of inflation; and the fluctuation of economic conditions, inflation and other global events on Aeries’ results of operations and global supply chain constraints. Further information on risks, uncertainties and other factors that could affect our financial results are included in Aeries’ periodic and current reports filed with the U.S. Securities and Exchange Commission. Furthermore, Aeries operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The forward-looking statements contained in this release are made as of the date hereof and Aeries disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.

Contact:
IR@aeriestechnology.com

CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except percentages)

	Three months ended September 30,						Six months ended September 30,
		2026			2025			2026			2025
Revenues, net	$	18,148		$	17,359		$	40,066		$	32,688
Cost of revenue		14,091			12,337			29,630			23,888
Gross profit	$	4,057		$	5,022		$	10,436		$	8,800
Gross profit margin		22.4	%		28.9	%		26.0	%		26.9	%
Operating expenses
Selling, general & administrative expenses		3,158			3,037			6,177			5,995
Total operating expenses	$	3,158		$	3,037		$	6,177		$	5,995
Income from operations	$	899		$	1,985		$	4,259		$	2,805
Other income / (expense)
Change in fair value of forward purchase agreement put option liability		–			(360	)		(7	)		895
Change in fair value of derivative warrant liabilities		82			(240	)		82			(217	)
Gain on settlement of forward purchase agreement put option liability		38			–			38			–
Interest income		79			76			156			148
Interest expense		(79	)		(94	)		(195	)		(263	)
Other income, net		766			69			543			77
Total other income / (expense)		886			(549	)		617			640
Income before income taxes		1,785			1,436			4,876			3,445
Income tax expense		(437	)		(794	)		(1,315	)		(1,125	)
Net income	$	1,348		$	642		$	3,561		$	2,320
Less: Net income attributable to noncontrolling interest		26			128			181			190
Less: Net income attributable to redeemable noncontrolling interests		46			273			322			375
Net income attributable to the shareholders of Aeries Technology, Inc.	$	1,276		$	241		$	3,058		$	1,755

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(In thousands, except percentages)

	Three months ended September 30,						Six months ended September 30,
		2026			2025			2026			2025
Net income	$	1,348		$	642		$	3,561		$	2,320
Income tax expense		437			794			1,315			1,125
Interest income		(79	)		(76	)		(156	)		(148	)
Interest expense		79			94			195			263
Depreciation and amortization		199			205			423			410
EBITDA	$	1,984		$	1,659		$	5,338		$	3,970
Adjustments
(+) Stock-based compensation		236			293			946			293
(-)/+ Change in fair value of derivative liabilities		(82	)		600			(75	)		(678	)
(-) Gain on settlement of forward purchase agreement put option liability		(38	)		–			(38	)		–
Adjusted EBITDA	$	2,100		$	2,552		$	6,171		$	3,585
Revenue		18,148			17,359			40,066			32,688
Adjusted EBITDA margin [Adjusted EBITDA / Revenue]		11.6	%		14.7	%		15.4	%		11.0	%

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In thousands)

Six months ended September 30,		2026			2025		$ Change			% Change
Cash and cash equivalents at the beginning of the period	$	4,878		$	2,764		$	2,114		76.5	%
Net cash provided by operating activities		4,740			2,394			2,346		98.0	%
Net cash used in investing activities		(462	)		(934	)		472		50.5	%
Net cash used in financing activities		(5,259	)		(2,328	)		(2,931	)	(125.9	)%
Effect of exchange rates on cash		(61	)		(30	)		(31	)	(103.3	)%
Cash and cash equivalents at the end of period	$	3,836		$	1,866		$	1,970		105.6	%

CONSOLIDATED BALANCE SHEET
(In thousands)

	As of September 30, 2026			As of March 31, 2026
ASSETS
Current assets:
Cash and cash equivalents	$	3,836		$	4,878
Accounts receivable, net of allowance of $1,630 and $1,335 as of September 30, 2026, and March 31, 2026, respectively		11,173			12,719
Prepaid expenses and other current assets, net of allowance of $1 and $0 as of September 30, 2026, and March 31, 2026, respectively		6,491			6,170
Deferred transaction costs		125			125
Total current assets	$	21,625		$	23,892
Property and equipment, net		1,807			1,750
Operating right-of-use assets		5,947			8,608
Deferred tax assets, net		4,399			3,689
Long-term investments, net of allowance of $52 and $52 as of September 30, 2026, and March 31, 2026, respectively		1,992			1,896
Other assets		2,400			2,059
Total assets	$	38,170		$	41,894
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS’ EQUITY / (DEFICIT)
Current liabilities:
Accounts payable	$	8,523		$	9,270
Accrued compensation and related benefits, current		3,465			3,568
Operating lease liabilities, current		1,187			2,694
Short-term borrowings		2,735			4,436
Forward purchase agreement put option liability		2,368			4,287
Other current liabilities		8,272			6,434
Total current liabilities	$	26,550		$	30,689
Long-term debt		782			798
Operating lease liabilities, noncurrent		5,164			6,358
Derivative warrant liabilities		339			421
Deferred tax liabilities		238			197
Other liabilities		5,760			6,016
Total liabilities	$	38,833		$	44,479
Commitments and contingencies
Redeemable noncontrolling interest		786			448
Shareholders’ equity / (deficit)
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding		–			–
Class A ordinary shares, $0.0008 par value; 62,500,000 shares authorized; 5,528,968 shares issued and outstanding as of September 30, 2026; 6,062,184 shares issued and outstanding as of March 31, 2026		5			5
Class V ordinary shares, $0.0001 par value; 1 share authorized, issued and outstanding		–			–
Net shareholders’ investment and additional paid-in capital		28,513			29,115
Less: Common stock held in treasury at cost; 690,812 shares as of September 30, 2026, and 374,744 shares as of March 31, 2026		(2,479	)		(1,304	)
Accumulated other comprehensive loss		(1,862	)		(1,977	)
Accumulated deficit		(25,814	)		(28,873	)
Total Aeries Technology, Inc. shareholders’ deficit	$	(1,637	)	$	(3,034	)
Noncontrolling interest		188			1
Total shareholders’ deficit	$	(1,449	)	$	(3,033	)
Total liabilities, redeemable noncontrolling interest and shareholders’ deficit	$	38,170		$	41,894

Source: Aeries Technology, Inc.

Second letter of intent under Sky Quarry’s Nevada Oil Development Program relates to two Nevada oil prospects near Sky Quarry’s Eagle Springs Refinery

WOODS CROSS, Utah, Nov. 11, 2026 (GLOBE NEWSWIRE) — Sky Quarry Inc. (Nasdaq: SKYQ), an energy infrastructure company focused on domestic refining and resource development, today announced that it has signed a non-binding letter of intent with BioForce Nanosciences Holdings, Inc. (BFNH) under which Sky Quarry will use commercially reasonable efforts to introduce BioForce, subject to BioForce’s prior written approval of each prospective financing source, to potential financing sources for BioForce’s Nevada oil exploration, drilling and development program. BioForce has advised Sky Quarry that it is seeking approximately $25 million for the program. The arrangement is non-exclusive, and BioForce retains sole discretion to accept or reject any financing proposal. This is the second letter of intent to emerge from Sky Quarry’s efforts to attract development capital to Nevada oil projects.

The agreement advances Sky Quarry’s Nevada Oil Development Program, announced August 5, 2026, which targets up to $50 million in third-party investment directly into qualified producers and projects. The BioForce opportunity illustrates how Sky Quarry intends to put that program to work by bringing a specific exploration project to potential financing sources and evaluating whether successful production could supply its Eagle Springs Refinery. The Nevada program is an initial component of Sky Quarry’s broader Great Basin Energy Initiative.

Two Prospects Across Nearly 20,000 Acres

BioForce has reported that it holds federal oil and gas leases covering approximately 19,957 acres in Nevada’s White River Valley. BioForce furnished an independent prospective resources assessment by Ryder Scott Company, L.P. with its August 18, 2026, Form 8-K. As reported by BioForce, the assessment presents the following gross, unrisked P50 estimates for the Fox Mountain and South Lund prospects. These are estimates of prospective resources, not reserves. Sky Quarry has not independently verified them.¹

Prospect	P50 Original Oil in Place	P50 Technically Recoverable Prospective Oil
Fox Mountain	8.085 billion barrels	1.349 billion barrels
South Lund	2.932 billion barrels	497 million barrels

“When we announced the Nevada program, we set out to find projects where we could help connect exploration capital with a potential local market for production,” said Marcus Laun, Interim Chief Executive Officer and President of Sky Quarry. “BioForce has assembled nearly 20,000 acres of federal leases and commissioned an independent prospective resources assessment. With this letter of intent, we have a specific project to introduce to potential financing sources, subject to BioForce’s approval. If drilling establishes commercial production, Foreland could offer a nearby market for crude that meets our refinery specifications, subject to a separate agreement on market-based terms.”

Potential Supply for Eagle Springs

Sky Quarry’s wholly owned subsidiary, Foreland Refining Corporation, operates the Eagle Springs Refinery near Ely, Nevada. If BioForce obtains financing and commences production, the parties intend to evaluate a potential crude oil purchase or offtake relationship. A new regional source of crude could diversify Foreland’s supply and reduce trucking distances. Any purchase would depend on commercial production, crude quality, volumes, pricing, transportation costs and refinery requirements, and would require a separate definitive agreement at market-based pricing. The letter of intent gives Sky Quarry no right of first refusal, right of first offer or other preferential right to BioForce’s production. BioForce remains free to sell its production to any purchaser.

Sky Quarry’s contemplated role under the letter of intent is limited to introducing BioForce to financing sources that BioForce has approved and assisting with related presentations. Sky Quarry does not guarantee that any financing will be obtained, and it has no obligation to provide financing from its own balance sheet. The letter of intent provides for no fee or other transaction-based compensation to Sky Quarry. Any investment would be subject to the financing source’s independent diligence and approval and to definitive agreements negotiated directly with BioForce. The $50 million figure is the Nevada program’s aggregate third-party investment target, not a commitment. Proceeds of any financing would go directly to BioForce or an agreed project entity, and Sky Quarry would not hold or control them. The financing is not intended to involve any issuance of Sky Quarry securities. The letter of intent is non-binding with respect to any financing or offtake transaction, has a term of 180 days, and may be terminated by either party at any time.

About Sky Quarry Inc.

Sky Quarry Inc. is an energy infrastructure company focused on domestic refining and resource development. Its wholly owned subsidiary, Foreland Refining Corporation, operates the Eagle Springs Refinery near Ely, Nevada, producing diesel, vacuum gas oil, naphtha and liquid paving asphalt. Sky Quarry is also developing its PR Spring facility in eastern Utah for hydrocarbon recovery. skyquarry.com

Forward-Looking Statements

This release contains forward-looking statements regarding potential financing introductions and investments, BioForce’s exploration and drilling plans, estimates of prospective resources, possible discoveries and commercial production, potential crude purchases and anticipated benefits to Sky Quarry’s refining operations. Actual results may differ materially due to financing availability, permitting, geological and drilling results, recovery performance, commodity prices, development and transportation costs, crude quality and the ability of the parties to enter into definitive agreements. Other risks include the non-binding nature of the letter of intent, either party’s right to terminate it at any time, and its non-exclusive nature. Exploration may yield no discovery, and any discovery may prove uneconomic. Prospective resource estimates are inherently uncertain and were prepared for BioForce, not Sky Quarry. Readers should review the risk factors in Sky Quarry’s SEC filings. Sky Quarry undertakes no obligation to update these statements except as required by law.

Investor Relations
ir@skyquarry.com

_{¹ Prospective resources are estimated quantities of oil that may potentially be recovered from undiscovered accumulations through future development projects. They carry both a risk of discovery and a risk of development, and they are not reserves. There is no certainty that any portion of the prospective resources will be discovered, or that it will be commercially viable to produce any portion that is discovered. The estimates shown are gross and unrisked and have not been adjusted for the chance of discovery or development.}

MONTREAL, Nov. 11, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results¹ for the third quarter ended September 30, 2026.

“In the third quarter of 2026, we continued to deliver on our commitment to operational excellence and strategy to become a geographically diversified, multi-asset ore processor,” said Daniel Misiano, President and CEO. “Record operational performance drove production and sales to the upper end of our guidance despite a stabilising gold environment. Based on continued momentum, we are reaffirming our full-year production and sales guidance and revising our net income guidance. Our inventory reduction and the gold price trend improved margins compared to the second quarter, and these are expected to normalise further in the fourth quarter.

We are steadily advancing our expansion pipeline, with the focus on disciplined growth. Production is ramping up at Galam, and we have launched operations at Svetlana with first ore feed. At Svetlana, commissioning will take slightly longer than planned due to extended equipment lead times but with no impact on our short-term outlook. In view of our three operations, we closed a gold purchase and prepayment facility, further strengthening our balance sheet and providing the financial flexibility to translate their cash flow potential into sustainable cash generation.”

Q3-2026 Highlights¹ 

• Record operational performance driven by robust throughput:  
  • Throughput of 48,373 tonnes (526 tpd), a new quarterly throughput record.
  • Record quarterly production of 34,716 gold-equivalent (AuEq) oz. on track to meet full-year production guidance.
  • Reduction of ore inventory to 75% of historical level by quarter-end.
     
• Financial:
  • Sales of $149.6 million, the third-highest quarterly sales.
  • Gross operating margin of $9.0 million, driven by high inventory at the beginning of the period and fluctuating gold prices throughout the period.
    • The higher inventory at quarter-start was mainly purchased at a higher gold price in the previous quarter.
    • Gold price was relatively stable in the period: flat in July, before increasing in August and falling in September to $4,150/oz.
  • EBITDA² of $6.7 million.
  • Net cash flows from operating activities before changes in working capital items of $4.0 million.
  • Net income of $2.9 million.
  • Cash gross operating margin of $285 per AuEq oz sold³.
  • Improved financial flexibility and balance sheet to fund working capital and capex requirements for three plants:
    • Cash position of $30.6 million as at September 30, 2026.
    • Subsequent to quarter-end, the Corporation entered into a $20 million unsecured gold purchase and prepayment facility.
• Steady execution of international expansion:
  • Senegal: Completion of first gold doré pour and commissioning; and ongoing ramp-up of plant to nameplate capacity of 50 tonnes per day.
  • Ecuador: Launch of Svetlana operations with first ore fed to the crushing circuit; mill rehabilitation some 82% complete; and launch of commissioning.
• Tax contingencies:
  • The Corporation is still awaiting the ruling from the Peruvian Tax Court with regard to its contested tax assessment for the 2015 fiscal year (maximum exposure of $8.6 million).

For more information regarding ongoing Peruvian tax audits and exposure, refer to note 20 “Other commitments and other contingencies” of the Corporation’s condensed interim consolidated financial statements as at September 30, 2026 and for the three and nine-month periods ended September 30, 2026 and 2025.

• Continued shareholder returns: Disbursed a monthly dividend representing CA$0.16 per share on an annual basis or a 3.1 % dividend yield based on the current share price.
• Corporate:
  • Appointment of Mr. Jonathan Hill as Chief Operating Officer of Dynacor in the quarter.
  • Signing of a Memorandum of Understanding with the World Gold Council to collaborate on the formalisation of the artisanal and small-scale gold mining sector.

Galam Pilot Plant in Senegal 

At the end of the quarter, the first gold doré pour was completed at Galam from gold-silver cement from the Merrill-Crowe circuit, with commissioning of all circuits performing within expectations. Construction was also completed and handed over to the operations team. Additional ore stockpiles were secured from new suppliers, supporting the ramp-up of operations in the fourth quarter of 2026. Dynacor expects the Senegal plant to exit the year at full nameplate throughput.

Figure 1: The Team Executing Galam’s Inaugural Pour

Svetlana Plant in Ecuador 

Rehabilitation of the Svetlana mill has reached 82% completion, with refurbishment of the main equipment in the crushing, grinding and leaching areas fully complete. As of quarter-end, $11.5 million had been spent and $4.0 million committed of the $22-$25 million projected capital expenditure.

Dry commissioning activities were launched at end of October in the crushing, grinding, and leaching circuits and first ore feed was achieved. Hot commissioning is scheduled for December, and ramp-up in Q1-2027.

Supplier network. To accelerate the plant ramp-up, Dynacor is developing a supplier network using its in-house Svetlana purchasing department and through, among others, its partnership with the United Nations’ planetGold program.

Regulatory applications advanced in the period, as Dynacor met with Ecuador’s Ministry of Production, Foreign Trade, Investments and Fisheries (MPCEI) to continue negotiations on its application for an Investment Protection Agreement.

Figure 2: Hopper loading ore into Svetlana’s crushing circuit

2026 Outlook versus Actuals

At quarter-end, the Corporation’s production and sales were tracking the upper end of 2026 guidance. Net income and capital expenditure guidance have been revised below.

	Original guidance	YTD	Revised guidance
Sales	$530-$580 million	$448.1 million	Unchanged
Net income	$22-$26 million	$11.3 million	$16-$18 million (2)
Production (in AuEq ounces)	125,000-135,000	99,414	Unchanged
Capital expenditure	$32.5-$39 million (1)	$20.6 million	$27-$30 million (3)

(1)	To achieve the 2026 growth plan and sustain current operations, of which $22-$25 million in Ecuador, $6-$8 million in Peru, $4-$5 million in Senegal and $0.5-$1 million in other jurisdictions.
(2)	Except for the impact of non-recurring items, if any. The guidance has been updated to reflect the impact of the gold price in Q2-2026 in addition to current gold prices and variances.
(3)	Due to the deferral of certain planned investments to 2027. The tightening of guidance is not expected to impact the Corporation’s 2026 operations.

A number of assumptions were made in preparing the 2026 outlook including

• Production range includes first ore from the Senegal and Ecuador plants. This estimate assumes that the Svetlana plant processes first ore in Q4-2026 and that operations exit the year at a throughput rate of approximately 150 tpd.
• Price of gold: $4,200 per ounce.
• No increase in installed operating capacity in Peru and steady ore supply.

The ore grade supplied may vary with the evolution of the gold price and the purchasing conditions. Final purchasing conditions in Ecuador and Senegal are yet to be determined.

As most of the Corporation’s cost of sales relates to the daily purchasing of ore, its margin and net income are favourably (unfavourably) impacted by the inventory level at quarter-start, the gradual appreciation (depreciation) of the gold price, and by the ore supply in the period.

Operations Overview

		Three-month ended September 30,						Nine-month ended September 30,
		2026			2025			2026			2025
Volume processed (in tonnes)		48,373			39,479			143,328			120,973
Tonnes per day		526			429			525			443
AuEq ounces produced		34,716			28,948			99,414			80,953

• During Q3-2026, the Corporation processed a record 48,373 tonnes (526 tpd on average),
  a new quarterly throughput record and a significant increase compared to Q3-2025.
• The strong production in Q3-2026 was mainly driven by the higher tonnes processed compared to
  Q3-2025.

Financial Overview

	Three-month ended September 30,						Nine-month ended September 30,
(in $’000) (unaudited)		2026			2025			2026			2025
Sales		149,585			100,515			448,095			260,189
Cost of sales		(140,604	)		(88,793	)		(416,094	)		(232,345	)
Gross operating margin		8,981			11,722			32,001			27,844
General and administrative expenses		(3,216	)		(3,513	)		(11,085	)		(9,232	)
Other project expenses		(51	)		(234	)		(134	)		(1,225	)
Operating income		5,714			7,975			20,782			17,387
Financial income (expenses), net		(57	)		219			(145	)		731
Write-off of exploration and evaluation assets		–			–			(4	)		(8	)
Foreign exchange gain (loss)		(205	)		13			(817	)		1,678
Income before income taxes		5,452			8,207			19,816			19,788
Current income tax expense		(2,544	)		(2,914	)		(8,491	)		(6,103	)
Deferred income tax (expense) recovery		(36	)		163			(3	)		389
Net income and comprehensive income		2,872			5,456			11,322			14,074
Earnings per share
Basic	$	0.07		$	0.13		$	0.27		$	0.34
Diluted	$	0.07		$	0.12		$	0.26		$	0.33

Q3-2026 Quarterly Results

• During Q3-2026, the gold price increased from an average of approximately $4,100/oz in July to around $4,400/oz in August, before ending the quarter at approximately $4,150/oz.
• Total sales amounted to $149.6 million compared to $100.5 million in Q3-2025. The $49.1 million increase is explained by the higher average gold sales price (+$26.3 million), in combination with the higher volumes of gold ounces sold (+$22.8 million) mainly due to the higher throughput.
• The Q3-2026 gross operating margin reached $9.0 million (6.0% of sales) compared to $11.7 million (11.7% of sales) in Q3-2025. The current quarter was impacted by the level of ore inventory at the beginning of the quarter and the gold price variance during August and September.
• General and administrative expenses totaled $3.2 million in Q3-2026 compared to $3.5 million in Q3-2025 (including $0.5 million of non-recurring expenses).
• Foreign exchange result was mainly impacted by the revaluation of monetary assets and liabilities denominated in Peruvian sol due to fluctuations in the Peruvian sol against the US dollar.
• A $2.6 million income tax expense was also recorded during Q3-2026, compared to $2.8 million in Q3-2025. The effective tax rate continues to be influenced by the variance throughout the period of the Peruvian sol against the US$, which is the Corporation’s functional currency. Future fluctuations will positively or negatively affect the current and deferred tax at the end of each period. The effective tax rate was also influenced by the withholding taxes on dividends received from one of our subsidiaries.

Q3-2026 Year-To-Date Results

• During the nine-month period ended September 30, 2026, the gold price increased from approximately $4,400/oz in January to approximately $5,400/oz in February, before declining to approximately $4,150/oz by the end of September, impacting the Corporation’s financial results for the period.
• Total sales for the nine-month period ended September 30, 2026, amounted to a record $448.1 million, compared to $260.2 million for the same period in 2025. The $187.9 million increase is explained by the higher average gold price (+$126.8 million), in combination with the higher quantities of gold-equivalent ounces sold (+$61.1 million) due to the higher throughput.
• General and administrative expenses for the nine-month period ended September 30, 2026, amounted to $11.1 million, compared to $9.2 million for the same period in 2025. The increase is primarily attributable to the expansion of the management team in the context of its international expansion.

Cash Flows, Working Capital and Liquidity Overview

	Three-month ended September 30,						Nine-month ended September 30,
(in $’000) (unaudited)	2026			2025			2026			2025
Operating activities
Net income, adjusted for non-cash items	4,044			6,601			15,628			16,556
Changes in working capital items	22,756			(12,947	)		5,906			(6,110	)
Net cash from (used in) operating activities	26,800			(6,346	)		21,534			10,446
Investing activities
Acquisition of the Svetlana plant	–			(9,948	)		–			(9,948	)
Change in short-term investments	–			2,998			–			5,998
Acquisition of property, plant and equipment, net of proceeds from disposal and other	(9,381	)		(3,262	)		(20,255	)		(5,384	)
Net cash used in investing activities	(9,381	)		(10,212	)		(20,255	)		(9,334	)
Financing activities
Issuance of common shares	–			–			–			20,433
Repurchase of common shares	–			(541	)		–			(1,703	)
Dividends paid	(1,195	)		(1,219	)		(3,642	)		(3,543	)
Other	(319	)		104			(339	)		178
Net cash (used in) from financing activities	(1,514	)		(1,656	)		(3,981	)		15,365
Change in cash during the period	15,905			(18,214	)		(2,702	)		16,477
Effect of exchange rate fluctuations on cash	(23	)		(297	)		(136	)		581
Cash, beginning of the period	14,768			55,388			33,488			19,819
Cash, end of the period	30,650			36,877			30,650			36,877

Investing activities

• On July 14, 2025, the Corporation completed the acquisition of 100% of the shares of the Svetlana processing plant in Ecuador for a total consideration of $9.75 million and incurred transaction costs of
  $0.2 million.
   
• In Q3-2026, Dynacor invested $9.5 million in capital expenditure of which $1.9 million was applied toward the construction of the ore-processing pilot plant in Senegal; $6.9 million toward the plant rehabilitation and vehicles in Ecuador; and $0.7 million in Peru, mainly to maintain or improve plant efficiency.

Working Capital and Liquidity

• As at September 30, 2026, the Corporation’s working capital amounted to $72.6 million, including $30.6 million in cash ($81.9 million, including $33.4 million in cash as at December 31, 2025). The variances are mainly due to the expected decrease in inventory and sales tax receivables.

Consolidated Statements of Financial Position

As at September 30, 2026, total assets amounted to $177.5 million ($181.5 million as at December 31, 2025). Major variances since year-end 2025 are mainly explained by additions to property, plant and equipment, partially offset by the decrease in sales tax receivables. The decline in trade and other payables is primarily due to the variance in unpaid inventories.

	As at September 30,		As at December 31,
(in $’000) (unaudited)	2026		2025
Cash	30,650		33,488
Accounts receivable	23,586		37,221
Inventories	33,890		39,016
Prepaid expenses and other assets	1,461		516
Current tax assets	1,737		2,158
Property, plant and equipment	66,571		49,442
Exploration and evaluation assets	18,583		18,575
Right-of-use assets	575		625
Deferred tax assets	416		418
Total assets	177,469		181,459
Trade and other payables	18,448		30,417
Asset retirement obligations	14,609		14,830
Lease liabilities	478		520
Share unit plan liabilities	1,135		790
Shareholders’ equity	142,799		134,902
Total liabilities and shareholders’ equity	177,469		181,459

About Dynacor

Dynacor Group is an ore-processing company dedicated to producing gold sourced from artisanal miners. Since our establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Cautionary Statement on Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Statements related to Dynacor projected revenues, earnings, growth rates, revenue and expansion plans, the estimated liability resulting from the tax reassessment by SUNAT, the result of the court hearing, the timing of delivery of the tax court decision and the Corporation’s defense of its position are forward looking statements as are any statements relating to future events, conditions or circumstances. The use of terms such as “believes”, “expects”, “will”, “intends”, “projects”, “anticipates”, “estimates”, “predicts”, “aims”, “targets”, “would”, “could”, “may”, “should”, “likely”, “plans”, “forecasts”, “continues”, or similar terms or the negative thereof are intended to assist in identification of these forward-looking statements. By its nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur and may cause actual results to differ materially from those anticipated in such forward-looking statements. Therefore, readers are cautioned not to place undue reliance upon any such forward-looking statements.

Forward-looking statements reflect management’s current beliefs and are based on information currently available to Dynacor. They are based on the following material assumptions, which management considers reasonable as of the date of this document: gold price; exchange rate; supply and quality of feedstock; operating and capital costs consistent with current estimates; timely receipt and renewal of required permits and licences; and no material change in the regulatory, tax or political environment in Perou, Ecuador and Senegal.

Many factors could cause the actual results of the Corporation to differ materially from the results, performance, achievements or developments expressed or implied by such forward-looking statements, including, without limitation, each of the following factors, which are discussed in further detail in the Corporation’s most recent annual information form available on SEDAR+ (www.sedarplus.ca): metal price volatility, foreign exchange rate and interest rate fluctuations, unexpected variations in geological conditions of a property or erroneous geological data, political, country and exportation risks, tax matters, supply and quality of feedstock, water supply, labour and employment relations, production and cost estimates, access to capital markets and future financing; execution of expansion; reputational risk; environmental matters, licenses and permits, competition, dependence on management, insurance risk, litigation, anti-corruption laws, mining industry and mining projects; risks related to statutory and regulatory compliance, cybersecurity threats, share price volatility, increased costs and compliance risks of being a public corporation and pandemics. The forward-looking statements contained herein are made as of the date of this document and are expressly qualified in their entirety by this cautionary statement. The Corporation disclaims any obligation to update or revise these forward-looking statements except as required by applicable law.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236
E: investors@dynacor.com
Website: http://www.dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com 
Website: www.renmarkfinancial.com

____________________

¹ All figures are in US dollars unless stated otherwise. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding.

² EBITDA: “Earnings before interest, taxes and depreciation” is a non-IFRS financial performance measure with no standard definition under IFRS Accounting Standards. It is therefore possible that this measure may not be comparable with a similar measure of another corporation. The Corporation uses this non-IFRS measure as an indicator of the cash generated by the operations and allows investors to compare the profitability of the Corporation with others by canceling effects of different asset bases, effects due to different tax structures as well as the effects of different capital structures. EBITDA is calculated on page 18 of the Corporation’s MD&A for the three- and nine-month periods ended September 30, 2026, with additional information provided in section 17, “Non-IFRS Measures.”

³ Cash gross operating margin per AuEq ounce is in US$ and is calculated by subtracting the average cash cost of sale per equivalent ounce of Au from the average selling price per equivalent ounce of Au and is a non-IFRS financial performance measure with no standard definition under IFRS Accounting Standards. It is therefore possible that this measure may not be comparable with a similar measure of another company. Cash gross operating margin per AuEq ounce is calculated on page 16 of the Corporation’s MD&A for the three and nine-month periods ended September 30, 2026, with additional information provided in section 17, “Non-IFRS Measures.”

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/28c2c68e-26e5-4e74-9210-92e76235af7e
https://www.globenewswire.com/NewsRoom/AttachmentNg/ecf7ade6-aee3-4797-abfb-0b39eaded27c

~RUM Group’s AI infrastructure business, Quake AI, named in NVIDIA’s announcement of Minerva, a new platform designed to support AI factory uptime and performance~

LONGBOAT KEY, Fla., Nov. 11, 2026 (GLOBE NEWSWIRE) — Quake AI, the AI infrastructure business of RUM Group Inc. (Nasdaq: RUM), today announced plans to deploy NVIDIA Minerva, a new AI operations platform designed to help operators identify infrastructure issues earlier and keep AI factories productive. The planned deployment is intended to strengthen the operational visibility behind Quake AI’s bare-metal compute offering.

NVIDIA named Quake AI among the companies planning to deploy NVIDIA Minerva in its October 22 announcement. Quake AI plans to use the platform to help its operations teams identify emerging issues and support the reliability and performance its customers expect.

“NVIDIA has powered our infrastructure for years, with more than 22,000 GPUs in operation today and NVIDIA Vera Rubin deployments planned for 2027,” said Chris Pavlovski, Founder and CEO of RUM Group. “Our customers choose bare-metal access because they want control over their compute. Delivering on that promise takes more than GPUs; it takes visibility into how the infrastructure is performing. NVIDIA Minerva will help our teams identify issues earlier and support the reliability, uptime and performance our customers expect.”

NVIDIA Minerva is an AI Native AIOps observability platform that ingests and correlates telemetry from GPUs, networking, storage, schedulers and AI workloads to help operators detect anomalies, identify likely root causes and anticipate emerging failures. By connecting those signals, the platform is designed to help teams move from reactive troubleshooting toward proactive maintenance and faster incident resolution.

Quake AI offers bare-metal GPU infrastructure for AI training and inference. The planned NVIDIA Minerva deployment reflects Quake AI’s focus on pairing direct access to compute with the operational discipline needed to support dependable performance at scale.

About RUM Group Inc.

RUM Group Inc. is an AI infrastructure and video company. Its Quake AI business delivers AI compute as a service, operating AI data centers including GPU and CPU compute, storage, and networking at scale. Rumble, RUM Group’s video business and the original tenant of Quake AI, provides creators and enterprises a full suite of video technologies, unlocking reach, scale, and monetization. RUM Group is building the rails of the agentic-first enterprise: the AI compute, cloud infrastructure, and trust layer for the agentic AI future, advancing RUM Group’s mission to maximize the power of human imagination. For more information, visit www.rum.group.

For investor inquiries, please contact:
Shannon Devine
MZ Group, MZ North America
203-741-8811
investors@rumble.com 

Source: RUM Group Inc

TROY, Mich., Nov. 11, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a global workforce strategy and solutions provider, today announced the Company will participate in the following upcoming investor conferences:

Southwest IDEAS Conference in Dallas: November 18, 2026

• Management is scheduled to present at 4:40 p.m. CT and will participate in one-on-one meetings with investors throughout the conference.

Wells Fargo 10th Annual TMT Summit in Rancho Palos Verdes, California: December 9, 2026

• Management is scheduled to present at 11:00 a.m. PT on December 9 and will participate in one-on-one meetings with investors throughout the conference.

Sidoti Small-Cap Virtual Conference: December 10, 2026

• Management will participate in one-on-one meetings with investors throughout the conference.

Truist Securities Human Capital Virtual Conference: December 14, 2026

• Management will participate in one-on-one meetings with investors throughout the conference.

Kelly’s investor presentation is available on the Company’s website.

About Kelly®

At Kelly® (Nasdaq: KELYA, KELYB), we don’t just understand the future of work, we’re defining it. For over 80 years, we’ve sourced specialized talent, built agile workforces, and shaped growth strategies for employers around the world. Today, our recruiting, outsourcing, and consulting services provide the talent and solutions organizations need to move faster and grow smarter. We deliver meaningful impact by connecting people to work that enriches their lives, and companies to people who drive innovation and growth. Each year, we place more than 375,000 job seekers in new roles spanning science, engineering, technology, telecom, education, manufacturing, and more. Revenue in 2025 was $4.3 billion. Learn more at kellyservices.com.

KLYA-FIN

ANALYST & MEDIA CONTACT:
Scott Thomas
(248) 251-7264    
scott.thomas@kellyservices.com

Revenue of $128 million, revenue growth of 23%
Net loss of $1.1 million. Adjusted Net Income⁽¹⁾ of $14.1 million
Adjusted EBITDA⁽¹⁾ margin improved to 19%, reaching $24.2 million
Free cash flow⁽¹⁾ of $10 million, a conversion of 41%
Reaffirming original full-year 2026 guidance and raising outlook to include IPS Group acquisition

HERZLIYA, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the third quarter ended September 30, 2026.

“Our third-quarter results demonstrated continued growth alongside improved margins, operating leverage and a return to positive free cash flow. Revenue grew 23%, gross margin hit a record 49.6%, and Adjusted EBITDA increased by more than 70% sequentially, all while we converted a 41% positive free cash flow. We completed the acquisition of IPS Group on October 1, 2026, expanding our platform into parking. Meanwhile, our new distribution partners are putting Nayax readers on more machines across more markets. With a strong Q4 order pipeline and IPS now contributing, we are well positioned for a strong finish to the year. As we move into 2027 and beyond, our focus shifts from investing to delivering, turning the partnerships and platforms we have built into recurring revenue and returns. We are still early in a long-term global shift, and Nayax is built to lead it,” commented Yair Nechmad, Nayax’s Co-Founder, Chief Executive Officer and Chairman of the Board.

(1)

Organic Revenue, Adjusted EBITDA, Free Cash Flow, Adjusted OPEX and Adjusted Net Income are non-IFRS financial measures. Please refer to footnote 3 in the table below and the additional tables at the end of this press release for a reconciliation of Organic Revenue, Adjusted EBITDA, Free Cash Flow, Adjusted OPEX and Adjusted Net Income to the most directly comparable IFRS measure for each. The Company does not provide a reconciliation of forward-looking Adjusted EBITDA and Adjusted Net Income to IFRS net income (loss) due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, in particular, because special items such as finance expenses and issuance and acquisition costs used to calculate projected net income (loss) can vary dramatically based on actual events. Therefore, the Company is not able to forecast on an IFRS basis with reasonable certainty all deductions needed in order to provide an IFRS calculation of projected net income (loss) at this time. The amount of these deductions may be material and therefore could result in projected IFRS net income (loss) being materially different than projected Adjusted EBITDA and Adjusted Net Income (non-IFRS).

Third Quarter 2026 Financial Highlights
All comparisons are relative to the third quarter and three-month period ended September 30, 2025, unless otherwise noted)
Revenue Summary	Q3 2026 ($M)	Q3 2025 ($M)	Growth (%)
Payment processing fees	58.9	47.7	23.5%
SaaS revenue	34.6	29.4	17.7%
Total recurring revenue (1)	93.5	77.1	21.3%
POS devices revenue (2)	34.5	27.2	26.8%
Total revenue (3)	128.0	104.3	22.7%
Margin Summary	Q3 2026	Q3 2025	Variance
Payment processing margin	41.6%	39.6%	+2.0%
SaaS margin	77.3%	76.3%	+1.0%
Total recurring margin	54.8%	53.6%	+1.2%
POS devices margin	35.2%	37.0%	–1.8%
Total margin	49.6%	49.3%	+0.3%

(1) Recurring revenue comprised of SaaS subscription revenue and payment processing fees.
(2) POS devices’ revenue includes revenues derived from the sale of our hardware products and other revenue.
(3) Organic Revenue is a non-IFRS financial measure that we define as total revenue adjusted to exclude the revenue attributable to acquired businesses for a period of 12 months following their acquisition. Total revenue for Q3 2026 includes $6.6 million of revenues from recent acquisitions.

• Revenue increased 23% to $128 million from $104.3 million, driven by both new and existing customer expansion.
• Organic Revenue ⁽³⁾ growth year to date was 21%.
• Recurring revenue from SaaS and payment processing fees grew 21%, to $93.5 million and represented 73% of total revenue.
• POS devices revenue increased by 27% to $34.5 million with strong demand for our products across all market segments, especially our EV platform as we strengthen our position in this important long-term growth market and capture market share.

• Gross margin was 49.6%:
  • Recurring margin improved to 54.8% from 53.6%, driven mainly by processing margin improvement to 41.6% from 39.6% reflecting the ongoing benefits of renegotiated contracts with several bank acquirers and the Company’s improved smart-routing capabilities. SaaS margin improved as well to 77.3% from 76.3%. Both processing and SaaS margins reflect the Company’s growing scale.
  • Hardware margin was 35.2%, which was a significant improvement sequentially from this year’s second quarter of 28.1% driven mainly by both a higher average selling price and a lower product cost of our VPOS Media product family.
• Operating income was $3.7 million compared to $7.8 million in last year’s third quarter. This year’s third quarter included stock-based compensation expenses of $6.2 million compared to $2.6 million in the prior year period. The increase is due to a new senior leadership stock-based incentive plan, that was initiated and disclosed last quarter. 
• Net financial expenses increased to $4.2 million compared to $3.3 million in the prior-year period, primarily reflecting higher expenses due to FX and interest expense associated with the bond issuances completed in 2025.
• The Company reported a net loss of $1.1 million for the quarter, compared to net income of $3.5 million in the prior year period due to higher financial expenses and stock-based compensation.
• Basic loss per share for the quarter ended September 30, 2026 was $(0.028) per share. Basic and diluted earnings per share for the third quarter ended September 30, 2025, were $0.095 and $0.092, respectively.
• Weighted average number of basic and diluted shares for the third quarter of 2026 were 37,928,190 and 41,435,453, respectively compared to 37,102,759 and 38,451,507 for the third quarter of 2025.

• Adjusted OPEX for the quarter was $40 million, which was an improvement of more than $4 million sequentially compared to the second quarter and represented 31.2% of revenue. Most of the improvements were related to several cost reduction initiatives such as employee-related, marketing and IT expenses.
• Adjusted EBITDA increased 32.9% to $24.2 million from $18.2 million, representing 19% of revenue as we continue to drive margin expansion, improve productivity and operational efficiency across the organization. Adjusted EBITDA in the third quarter increased by more than 70% sequentially compared to the second quarter, which reflects the operating leverage of the business from both an improvement in overall gross margin as well as disciplined cost management.
• Adjusted net income for the quarter was $14.1 million, compared to adjusted net income of $10.2 million in the prior-year period.
• Basic and diluted adjusted net income per share was $0.372 and $0.341, respectively, for the third quarter of 2026 compared to $0.275 and $0.265, respectively, for the third quarter of 2025.

• Cash flow provided from operating activities for the third quarter was $18.1 million.
• Free Cash Flow for the third quarter was $10 million compared to $3.9 million in the prior-year quarter.
• As of September 30, 2026, cash, cash equivalents and short-term deposits totaled $453 million, while total short- and long-term debt stood at $491 million. Both include $150 million of bank loans to finance the IPS acquisition which was completed on October 1, 2026 for a total cash consideration of $350 million.

Third Quarter 2026 Operational Metric Highlights
Key Performance Indicators	Q3 2026	Q3 2025	Growth (%)
Total transaction value ($m)	2,213	1,763	25.5%
Number of processed transactions (millions)	839	736	14.0%
Take rate (payments) (4)	2.66%	2.71%	-0.05%
Managed and connected devices (thousands)	1,598	1,433	11.5%
Customers	130,800	109,600	19.3%
ARPU ($) (5)	255	230	10.9%

(4) Payment service providers typically take a percentage of every transaction in exchange for facilitating the movement of funds from the buyer to the seller. Take rate % (payments) is calculated by dividing the Company’s processing revenue by the total dollar transaction value in the same quarter.
(5) Average revenue per unit (ARPU) is calculated using recurring revenue divided by the number of connected devices over a 12-month trailing period.

• Total transaction value grew by 25.5% to $2.2 billion. 
• Number of processed transactions increased 14% to 839 million.
• Take rate was strong at 2.66%.
• The customer base grew 19.3% year over year to approximately 131,000, with approximately 5,400 new customers added in the third quarter of 2026.
• ARPU increased to $255, representing a 10.9% increase driven by the continued conversion of existing machines from cash payments to cashless payments, and our expansion into verticals with higher transaction values, such as EV charging, amusement facilities, and car washes.

Recent Business Highlights

• Completed Acquisition of IPS Group. Nayax completed its acquisition of IPS Group, a leading provider of payment-enabled smart parking technology. IPS brings a market-leading smart parking platform and an installed base of more than 250,000 parking spaces across the United States, Canada, the United Kingdom, and Ireland. Nayax will strengthen the platform with its global payments infrastructure and extend it internationally through its commercial presence in over 120 countries, starting with Continental Europe, while expanding Nayax’s addressable cashless opportunity.
• Announced a Distribution Partnership with Allied Electronics, Inc. Through the partnership, Nayax Fuel’s VPOS Media 5 outdoor payment solution will reach fuel retailers across the United States alongside Allied. Allied has served the retail petroleum industry since 1978, and its systems, including the NeXGen PRIME forecourt controller, operate at tens of thousands of locations nationwide. The partnership brings Nayax payment infrastructure to US fuel retailers through a partner they know and trust. Card payments now make up 81% of US pump transactions, up from 64% a decade ago, according to NACS.
• Announced a Global Strategic Partnership with Getnet. Together, Nayax and Getnet will bring integrated payment acceptance to operators of vending machines, EV chargers, self-service kiosks, and other unattended businesses across Latin America and Iberia. Nayax will roll out across Getnet’s acquiring network, starting in Chile and expanding to Spain, Portugal, Brazil, Mexico, and Argentina. The partnership is expected to open new Latin American markets for Nayax and strengthens its regional presence.
• Launched its Electric Mobility Business in Brazil. The VPOS Media 4 Mini lets drivers pay directly at the charger with cards and digital wallets. The terminal is certified by ABECS, which governs payment security in Brazil, and by Anatel, which covers connected devices. It is built for unattended outdoor sites and is available across Brazil.

2026 Financial Outlook 

The Company is reaffirming its guidance for the full year, excluding IPS, of $510 million to $520 million, including organic revenue growth of 22% to 25%. IPS is expected to contribute approximately $20 million of revenue in the fourth quarter, therefore with IPS, the Company’s revenue guidance is expected to be between $530 million and $540 million for the full year 2026.

Similarly, Adjusted EBITDA for the year is now expected to be approximately $90 million to $95 million, which again we are reaffirming our original guidance of $85 million to $90 million plus the expected contribution of approximately $5 million from IPS in the fourth quarter.

The Company continues to expect free cash flow conversion from Adjusted EBITDA of approximately 5% to 10% for the year, excluding the expected contribution of IPS. As stated last quarter, this primarily reflects accelerated investments the Company is making to support its long-term growth initiatives. The areas of investment are in financial services including lending, installment and issuing capabilities, as well as capturing market share in the EV charging space, and securing sourcing of key components and costs.

Mid-term Outlook 

With respect to Nayax’s mid-term 2028 outlook, which was introduced shortly after its IPO in 2021, the Company continues to make measurable progress. The framework includes revenue of $1.0 billion driven by a combination of organic growth and strategic M&A, gross margin of 50%, and Adjusted EBITDA margin of 30%, as we continue to drive high margin recurring revenues and operational efficiency.

It is noted that the financial outlook provided by Nayax constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks and is current as of today. Unless required by law, Nayax has no obligation to update its guidance. Please see the cautionary note regarding forward-looking statements below. 

Investor Conference Calls

Nayax will host two conference calls to discuss its results later today, November 11, 2026. The first will be in English for international investors and the second in Hebrew for Israel-based investors to discuss its third quarter 2026 results.

The conference call in English will be held at: 8:30 a.m. Eastern Time / 3:30 p.m. Israel Time / 5:30 a.m. Pacific Time. The conference call in Hebrew will be held at: 10:00 a.m. Eastern Time / 5:00 p.m. Israel time / 7:00 a.m. Pacific Time.

Participating in the calls will be Yair Nechmad, Chief Executive Officer, Sagit Manor, Chief Financial Officer, and Aaron Greenberg, Chief Strategy Officer.

For the conference call in English, Nayax encourages participants to pre-register using the link below. Those who pre-register will be given a unique PIN to gain immediate access to the call, bypassing the live operator. Participants may pre-register any time, including up to and after the call/webcast start time. Participants will immediately receive an online confirmation, an email with the dial in number and a calendar invitation for the event.

To pre-register, go to: http://services.incommconferencing.com/DiamondPassRegistration/register?confirmationNumber=13763495&linkSecurityString=1f59a992e1

For those who are unable to pre-register, kindly join the conference call/webcast by using one of the dial-in numbers or clicking the webcast link below.

• U.S. TOLL-FREE: 1-877-737-7051
• ISRAEL TOLL-FREE: 1-809-455-690
• INTERNATIONAL: 1-201-689-8878

WEBCAST LINK: 

https://viavid.webcasts.com/starthere.jsp?ei=1780371&tp_key=7415856c81

Following the conference call, a replay will be available until November 25, 2026. To access the replay, please dial one of the following numbers:

• Replay TOLL-FREE: 1-844-512-2921
• Replay TOLL/INTERNATIONAL: 1-412-317-6671
• Access PIN: 13763495

An archive of the conference call will also be available on Nayax’s Investor Relations website Nayax – Investor Relations.

To access the conference call/webcast in Hebrew, use the link: 

https://events.teams.microsoft.com/event/5752d030-22bd-4ddb-9d73-e0386bfa4cf5@7a4ff859-325c-4962-8c3e-13258b1ee769?source=copyLinkLegacyShareEventDialog

About Nayax

Nayax is a global commerce enablement, payments and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. With foundations and global leadership in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across multiple channels. As of September 30, 2026, Nayax has 13 global offices, approximately 1,200 employees, connections to more than 80 merchant acquirers and payment method integrations and is globally recognized as a payment facilitator. Nayax’s mission is to improve our customers’ revenue potential and operational efficiency — effectively and simply. For more information, please visit www.nayax.com.

Public Relations Contact: Scott Gamm Strategy Voice Associates Scott@strategyvoiceassociates.com

Investor Relations Contact: Aaron Greenberg Chief Strategy Officer IR@nayax.com

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others. Forward-looking statements include, but are not limited to, statements regarding our intent, belief or current expectations, such as statements in this press release regarding our financial outlook, future business prospects and the impact of recent acquisitions or partnerships published by the Company. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: our expectations regarding general market conditions, including as a result of global economic trends; changes in consumer tastes and preferences; fluctuations in inflation, interest rate and exchange rates in the global economic environment; the availability of qualified personnel and the ability to retain such personnel; changes in commodity costs, labor, distribution and other operating costs; our ability to implement our growth strategy; changes in government regulation and tax matters; other factors that may affect our financial condition, liquidity and results of operations; general economic, political, demographic and business conditions in Israel; the success of operating initiatives, including advertising and promotional efforts and new product and concept development by us and our competitors; and other risk factors discussed under “Risk Factors” in our annual report on Form 20-F filed with the SEC on March 9, 2026 (our “Annual Report”). The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only estimates based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under “Risk Factors” in our Annual Report. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Each forward-looking statement speaks only as of the date of the particular statement. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

Use of Non-IFRS Financial Information

In addition to various operational metrics and financial measures in accordance with accounting principles generally accepted under International Financial Reporting Standards, or IFRS, this press release contains financial metrics presented on a constant currency basis as well as Adjusted EBITDA and Free Cash Flow, each of which are non-IFRS financial measures, as a measure to evaluate our past results and future prospects.

Constant Currency

Nayax presents constant currency information to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency rate fluctuations. Future expected results for transactions in currencies other than United States dollars are converted into United States dollars using the exchange rates in effect in the last month of the reporting period. Nayax provides this financial information to aid investors in better understanding our performance. The constant currency financial measures presented in this release should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS.
The Company cannot provide expected net income without unreasonable effort because certain items that impact net income are out of the Company’s control and/or cannot be reasonably predicted at this time, of which unavailable information could have a significant impact on the Company’s IFRS financial results.

Organic Revenue

Organic Revenue is a non-IFRS financial measure that we define as total revenue adjusted to exclude the revenue attributable to acquired businesses for a period of 12 months following their acquisition. This measure helps provide insight on organic and acquisition-related growth and presents useful information about comparable revenue growth.

Free Cash Flow

Free Cash Flow is a non-IFRS financial measure that we define as net cash provided from operating activities minus capitalized development costs and acquisition of property and equipment. A reconciliation is provided at the end of this press release for Free Cash Flow to Net cash provided from operating activities, the most directly comparable financial measure prepared in accordance with IFRS.

Adjusted OPEX

Adjusted OPEX is a non-IFRS financial measure that we define as total OPEX excluding stock based compensation, depreciation and amortization and other expenses.

Adjusted EBITDA

Adjusted EBITDA is a non-IFRS financial measure that we define as loss for the period excluding finance expenses, tax expense (benefit), depreciation and amortization, share-based compensation costs, non-recurring issuance and acquisition costs, our share in losses of associates accounted for by the equity method and other expenses.
We present Adjusted EBITDA in this press release because it is a measure that our management and board of directors utilize as a measure to evaluate our operating performance and for internal planning and forecasting purposes. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We believe that Adjusted EBITDA, when taken collectively with financial measures prepared in accordance with IFRS, may be helpful to investors because it provides an additional tool for investors to use in evaluating our ongoing operating results and trends and in comparing our financial results with other companies because it provides consistency and comparability with past financial performance. However, our management does not consider this non-IFRS measure in isolation or as an alternative to financial measures determined in accordance with IFRS.

Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS. Adjusted EBITDA may be different from similarly titled measures used by other companies. The principal limitation of Adjusted EBITDA is that it excludes significant expenses that are required by IFRS to be recorded in our financial statements, as further detailed above. In addition, it is subject to inherent limitations as it reflects the exercise of judgment by management about which expenses are excluded or included in determining Adjusted EBITDA.

A reconciliation is provided at the end of this press release for Adjusted EBITDA to net profit or loss, the most directly comparable financial measure prepared in accordance with IFRS. Investors are encouraged to review net loss and the reconciliation to Adjusted EBITDA included below and to not rely on any single financial measure to evaluate our business.

Adjusted Net Income

Adjusted Net Income is a non-IFRS financial measure that we define as the net income or loss for the period, plus share-based compensation costs, one time and non-recurring items cost such as restructuring and M&A costs, amortization of acquired intangibles and gains or losses on equity investments, and other expenses.

Other Financial Metrics – Dollar-based net retention rate

Measured as a percentage of Recurring Revenue from returning customers in a given period as compared to the Recurring Revenue from such customers in the prior period, which reflects the increase in revenue and the rate of losses from customer churn.

                                                  

NAYAX LTD

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

As of September 30, 2026
(Unaudited)

NAYAX LTD CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
	September 30		December 31
	2026		2025
	U.S. dollars in thousands
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	452,072		319,538
Restricted cash transferable to customers for processing activity	111,943		91,965
Short-term bank deposits	1,245		1,171
Receivables in respect of processing activity	48,215		47,865
Trade receivable, net	114,312		103,975
Inventory	31,896		28,594
Other current assets	44,248		27,056
Total current assets	803,931		620,164
NON-CURRENT ASSETS:
Long-term bank deposits	216		211
Other long-term assets	9,167		8,596
Right-of-use assets, net	11,011		8,911
Property and equipment, net	22,406		20,362
Goodwill and intangible assets, net	206,885		190,493
Deferred income tax assets	4,860		3,901
Total non-current assets	254,545		232,474
TOTAL ASSETS	1,058,476		852,638

NAYAX LTD CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
	September 30		December 31
	2026		2025
	U.S. dollars in thousands
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Short-term bank credit and short-term loan	156,053		–
Current maturities of long-term bank loans	3,220		3,220
Current maturities of debentures	32,874		–
Current maturities of other long-term liabilities	2,904		5,538
Current maturities of leases liabilities	4,324		3,474
Payables in respect of processing activity	212,287		180,795
Trade payables	19,516		29,370
Other payables	52,083		52,021
Total current liabilities	483,261		274,418
NON-CURRENT LIABILITIES:
Long-term bank loans	8,050		10,465
Other long-term liabilities	3,379		9,329
Debentures	290,838		314,064
Lease liabilities	7,641		6,402
Deferred income taxes	8,669		6,945
Total non-current liabilities	318,577		347,205
TOTAL LIABILITIES	801,838		621,623
EQUITY:
Shareholders Equity:
Share capital	9		9
Additional paid in capital	254,492		242,759
Capital reserves	12,355		7,882
Accumulated deficit	(10,218)		(19,635)
TOTAL EQUITY	256,638		231,015
TOTAL LIABILITIES AND EQUITY	1,058,476		852,638

NAYAX LTD CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (UNAUDITED)
	Nine months ended September 30				Three months ended September 30
	2026		2025		2026		2025
	U.S. dollars in thousands
	(Excluding Profit per share data)
Revenues	357,483		280,979		128,037		104,280
Cost of revenues	(184,306)		(143,542)		(64,581)		(52,914)
Gross Profit	173,177		137,437		63,456		51,366
Research and development expenses	(27,800)		(23,705)		(9,190)		(8,821)
Selling, general and administrative expenses	(126,646)		(88,766)		(41,390)		(30,007)
Depreciation and amortization in respect of technology and capitalized development costs	(11,992)		(10,428)		(4,113)		(3,926)
Other income (expenses)	(5,558)		10,944		(5,065)		(766)
Share of losses of equity method investees	–		(226)		–		–
Operating Income	1,181		25,256		3,698		7,846
Financial Income	9,191		8,461		1,796		1,685
Financial Expense	(18,586)		(9,761)		(5,986)		(4,962)
Profit (loss) before taxes on income	(8,214)		23,956		(492)		4,569
Tax expenses	(1,699)		(1,611)		(584)		(1,032)
Profit (loss) for the period	(9,913)		22,345		(1,076)		3,537
Earnings per share attributed to shareholders of the Company:
Basic earnings (loss) per share	(0.263)		0.605		(0.028)		0.095
Diluted earnings (loss) per share	(0.263)		0.584		(0.028)		0.092

  

NAYAX LTD CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
	Nine months ended September 30				Three months ended September 30
	2026		2025		2026		2025
	U.S. dollars in thousands
Profit (loss) for the period	(9,913)		22,345		(1,076)		3,537
Other comprehensive income (loss) for the period:
Items that may be reclassified to profit or loss:
Gain from translation of financial statements of foreign operations	284		852		688		323
Gain (loss) on cash flow hedges	4,189		1,383		166		(650)
Total other comprehensive income (loss) for the period	4,473		2,235		854		(327)
Total comprehensive income (loss) for the period	(5,440)		24,580		(222)		3,210

  

NAYAX LTD CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
	Share capital		Additional paid in capital		Remeasurement of post- employment benefit obligations		Other capital reserves		Foreign currency translation reserve			Accumulated deficit			Total equity
	U.S. dollars in thousands
Balance as of January 1, 2025 (audited)	9		220,715		463		9,973		(2,604)			(63,311)			165,245
Changes in the nine months ended September 30, 2025:
Profit for the period	–		–		–		–		–			22,345			22,345
Issuance of warrants, net	–		5,706		–		–		–			–			5,706
Issuance of options due acquisition	–		1,222		–		–		–			–			1,222
Other comprehensive income for the period	–		–		–		1,383		852			–			2,235
Employee options exercised and vesting of RSUs	*		3,580		–		–		–			–			3,580
Share-based payment	–		–		–		–		–			7,781			7,781
Balance as of September 30, 2025 (unaudited)	9		231,223		463		11,356		(1,752)			(33,185)			208,114
Balance as of January 1, 2026 (audited)	9		242,759		516		10,391		(3,025)			(19,635)			231,015
Changes in the nine months ended September 30, 2026:
Loss for the period	–		–		–		–		–			(9,913)			(9,913)
Other comprehensive income for the period	–		–		–		4,189		284			–			4,473
Employee options exercised and vesting of RSUs	*		11,733		–		–		–			–			11,733
Share-based payment	–		–		–		–		–			19,330			19,330
Balance as of September 30, 2026 (unaudited)	9		254,492		516		14,580		(2,741)			(10,218)			256,638

(*) Presents an amount less than $1 thousand.

NAYAX LTD CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
	Share capital		Additional paid in capital		Remeasurement of post- employment benefit obligations		Other capital reserves			Foreign currency translation reserve			Accumulated deficit			Total equity
	U.S. dollars in thousands
Balance as of June 30, 2025 (unaudited)	9		230,733		463		12,006			(2,075	)		(39,649	)		201,487
Changes in the three months ended September 30, 2025:
Profit for the period	–		–		–		–			–			3,537			3,537
Other comprehensive income for the period	–		–		–		(650	)		323			–			(327	)
Employee options exercised and vesting of RSUs	*		490		–		–			–			–			490
Share-based payment	–		–		–		–			–			2,927			2,927
Balance as of September 30, 2025 (unaudited)	9		231,223		463		11,356			(1,752	)		(33,185	)		208,114
Balance as of June 30, 2026 (unaudited)	9		245,823		516		14,414			(3,429	)		(11,952	)		245,381
Changes in the three months ended September 30, 2026:
Loss for the period	–		–		–		–			–			(1,076	)		(1,076	)
Other comprehensive income for the period	–		–		–		166			688			–			854
Employee options exercised and vesting of RSUs	*		8,669		–		–			–			–			8,669
Share-based payment	–		–		–		–			–			2,810			2,810
Balance as of September 30, 2026 (unaudited)	9		254,492		516		14,580			(2,741	)		(10,218	)		256,638

(*) Presents an amount less than $1 thousand.

NAYAX LTD
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Nine months ended September 30				Three months ended September 30
	2026		2025		2026		2025
	U.S. dollars in thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net profit (loss) for the period	(9,913)		22,345		(1,076)		3,537
Adjustments required to reflect the cash flow from operating activities (see Appendix A)	30,312		2,352		19,156		6,925
Net cash provided by operating activities	20,399		24,697		18,080		10,462
CASH FLOWS FROM INVESTING ACTIVITIES:
Capitalized development costs	(24,345)		(17,025)		(7,181)		(4,537)
Acquisition of property and equipment	(5,142)		(3,977)		(851)		(2,071)
Loans granted to related companies and others	(493)		(2,062)		(1,301)		–
Decrease (Increase) in bank deposits	(1,000)		4,926		(1,000)		(4,080)
Interest received	8,354		4,382		2,705		1,509
Investments in financial assets and other assets	(270)		(5,000)		–		–
Proceeds from sub-lessee	–		22		–		–
Payments for acquisitions of subsidiaries, net of cash acquired	–		(15,541)		–		–
Payment of deferred consideration and contingent liability due consideration of subsidiary acquisition	(15,161)		(8,287)		(9,635)		(2,768)
Net cash used in investing activities	(38,057)		(42,562)		(17,263)		(11,947)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issue of debentures and warrants, net	–		132,941		–		–
Interest paid	(20,254)		(6,806)		(10,084)		(5,208)
Changes in short-term bank credit and short-term loan	156,053		(26,000)		156,053		–
Repayment of long-term bank loans	(2,415)		(7,884)		(805)		(805)
Repayment of other long-term liabilities	–		(1,000)		–		–
Employee options exercised	12,197		4,067		9,041		1,387
Principal lease payments	(2,897)		(2,200)		(973)		(767)
Net cash provided by (used in) financing activities	142,684		93,118		153,232		(5,393)
Increase (Decrease) in cash and cash equivalents	125,026		75,253		154,049		(6,878)
Balance of cash and cash equivalents at beginning of period	319,538		83,130		302,827		172,267
Gains (losses) from exchange differences on cash and cash equivalents	6,511		8,663		(4,926)		1,774
Gains from translation of cash and cash equivalents of foreign operation	997		248		122		131
Balance of cash and cash equivalents at end of period	452,072		167,294		452,072		167,294

NAYAX LTD CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
	Nine months ended September 30				Three months ended September 30
	2026		2025		2026		2025
	U.S. dollars in thousands
Appendix A – adjustments to reconcile net profit (loss) to net cash provided by operations:
Adjustments in respect of:
Depreciation and amortization	23,804		18,565		9,055		6,830
Post-employment benefit obligations, net	(53)		45		(81)		10
Deferred taxes	(2,186)		(1,569)		(663)		(497)
Finance expenses, net	8,103		5,371		3,725		1,690
Income from gaining control in subsidiary	–		(12,152)		–		–
Expenses related to employee benefit	3,425		–		3,425		–
Share of loss of equity method investee	–		226		–		–
Long-term deferred income	(1,241)		144		(278)		39
Expenses in respect of share-based compensation	20,895		6,857		6,248		2,562
Total adjustments	52,747		17,487		21,431		10,634
Changes in operating asset and liability items:
Decrease (Increase) in restricted cash transferable to customers for processing activity	(19,978)		(31,089)		17,970		(10,654)
Decrease (Increase) in receivables from processing activity	(350)		(15,553)		10,030		19,794
Increase in trade receivables	(9,744)		(9,328)		(389)		(5,033)
Increase in other current assets	(8,433)		(4,847)		126		(2,399)
Increase in inventory	(3,154)		(3,238)		(1,913)		(740)
Increase (Decrease) in payables in respect of processing activity	31,492		50,134		(20,430)		(7,078)
Increase (Decrease) in trade payables	(10,058)		(6,304)		(7,949)		1,386
Increase (Decrease) in other payables	(2,210)		5,090		280		1,015
Total changes in operating asset and liability items	(22,435)		(15,135)		(2,275)		(3,709)
Total adjustments required to reflect the cash flow from operating activities	30,312		2,352		19,156		6,925
Appendix B – Information regarding investing and financing activities not involving cash flows:
Purchase of property and equipment on credit	197		154		–		–
Recognition of right-of-use assets through lease liabilities	4,900		117		3,679		117
Share based payments costs attributed to development activities, capitalized as intangible assets	2,373		924		500		365

IFRS to Non-IFRS Reconciliation
The following is a reconciliation of Net Income/(Loss) for the period, the most directly comparable IFRS financial measure, to Adjusted EBITDA for each of the periods indicated.

Quarter ended (U.S. dollars in thousands)
	Sep 30, 2026	Sep 30, 2025
Net income/(loss) for the period	(1,076)	3,537
Finance expense, net	4,190	3,277
Income tax expense	584	1,032
Depreciation and amortization	9,055	6,830
EBITDA	12,753	14,676
Share-based payment costs	6,248	2,562
Employment benefit cost(1)	130	196
Other expenses(2)	5,065	766
Adjusted EBITDA	24,196	18,200

(1)	Primarily other compensation arrangements provided to the shareholders of VMT
(2)	Other Expenses for Q3 2025 are mainly payroll expenses due to restructuring. Other Expenses for Q3 2026 are mainly due to the amendment to the consideration related to VM Tecnologia acquisition

The following is a reconciliation of Net Income/(Loss) for the period, the most directly comparable IFRS financial measure, to Adjusted Net Income for each of the periods indicated.

Quarter ended (U.S. dollars in thousands)
	Sep 30, 2026	Sep 30, 2025
Net income/(loss) for the period	(1,076)	3,537
Share-based payment costs	6,248	2,562
Employment benefit cost(1)	130	196
Other expense(2)	5,065	766
Amortization of acquired intangibles(3)	3,746	3,138
Adjusted net income for the period	14,113	10,199

(1)	Primarily other compensation arrangements provided to the shareholders of VMT
(2)	Other Expenses for Q3 2025 are mainly payroll expenses due to restructuring. Other Expenses for Q3 2026 are mainly due to the amendment to the consideration related to VM Tecnologia acquisition
(3)	Includes deferred tax income related to amortization of acquired intangibles

     

The following is a reconciliation of Operating Cash for the period, the most directly comparable IFRS financial measure, to Free Cash Flow for each of the periods indicated.

Quarter ended (U.S. dollars in thousands)
	Sep 30, 2026	Sep 30, 2025
Operating Cash	18,080	10,462
Capitalized development costs	(7,181)	(4,537)
Acquisition of property and equipment	(851)	(2,071)
Free Cash Flow	10,048	3,854

The following is a reconciliation of OPEX for the period, the most directly comparable IFRS financial measure, to Adjusted OPEX for each of the periods indicated.

Quarter ended (U.S. dollars in thousands)
	Sep 30, 2026	Sep 30, 2025
OPEX	54,693	42,754
Stock Based Compensation	(6,064)	(2,469)
Depreciation & Amortization	(8,578)	(6,472)
Employment Benefit Cost(1)	(130)	(196)
Adjusted OPEX	39,921	33,617

(1)	Primarily other compensation arrangements provided to the shareholders of VM

• Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue
• Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living medicines toward room temperature deployability
• Randomized Phase 2 ARDS trial of agenT-797 plus standard of care (SOC) enrolling with U.S. dosing expected before year-end in patients with ~40% 28-day mortality, no effective approved therapies (estimated 93,000 U.S. patients annually)
• Data presented at SITC 2026: agenT-797 and MiNK-215 acted as “living senolytics,” clearing senescent cells chemotherapy leaves behind – cells that fuel treatment resistance and fibrotic lung disease; agenT-797 also unlocked tumor-cell killing with BOT/BAL in LM MSS CRC  organoids
• Disciplined execution: 23% year-over-year improvement in net loss per share, 44% G&A efficiency gain and the most capital-efficient quarter of 2026

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies, reported financial results for the third quarter ended September 30, 2026, and highlighted a quarter in which agenT-797 realized pre-commercial revenue, its randomized trial in acute respiratory distress syndrome (ARDS) is advancing , and an ARPA-H program selected the Company’s cells to generate living medicines can be delivered without a freezer. Full financial results will be reported on Thursday, November 12, 2026.

iNKT cells coordinate the immune response a tissue requires: resolving infection and inflammation in severe lung injury, overcoming treatment resistance in cancer and clearing the senescent cells that sustain progression and fibrotic scarring. agenT-797 delivers from inventory – without apheresis, HLA matching or lymphodepletion. MiNK is concentrating its own investment on the randomized ARDS trial and using non-dilutive partners to advance key platform programs.

“We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. “The same unmodified iNKT cells, from the same donor, that drove a 77% disease control rate in PD-1-refractory gastroesophageal cancer are now in a placebo-controlled trial in ARDS, where nearly four in ten patients die and no effective approved drug changes that outcome. Our focus now is delivering the randomized readout designed to show what these cells can do for these patients.”

Third Quarter 2026 and Recent Highlights

Named-Patient Access Reaches Patients in Multiple Countries, Generating First Pre-commercial Revenue

In the third quarter, MiNK recognized its first pre-commercial product revenue from agenT-797 supplied on a paid, per-patient basis under its international named-patient access program, in collaboration with Orphan Drug Consulting and BAP. The program is now open in multiple countries outside the United States. Every request originates with a treating physician for an individually identified patient with serious unmet medical need and is authorized case by case by the applicable health authority; agenT-797 remains investigational.

The program shows that MiNK’s inventory can supply trials and physician-directed access at the same time; that MiNK can move a living cell therapy across borders with full regulatory and safety oversight; and that physicians are requesting it. MiNK intends to expand this access in all markets where regulations allow. 

Randomized ARDS Trial Advancing 

MiNK’s randomized, placebo-controlled Phase 2 study of agenT-797 plus standard of care in adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure (C-1300-02) continued enrolling in Lviv, Ukraine during the quarter. U.S. dosing is expected before year-end, with data expected 2H2027.

MiNK plans to advance C-1300-02 as an adaptive trial. The initial randomized stage would enroll 124 patients for initial readout in 2H2027 for the potential to expand. MiNK is pursuing a hierarchical design which will evaluate prevention of patients advancing to veno-venous ECMO and all-cause mortality through Day 28. MiNK is seeking FDA feedback on the development plans for the program.

In August, MiNK presented initial Day 28 observations from the first agenT-797-treated patients at the Military Health System Research Symposium. These very sick patients, several with multidrug-resistant infections, demonstrated resolution of fever, improved oxygenation, resolution of ARDS and recovery from ventilator and vasopressor support, with immune markers in blood and lung fluid tracking recovery. No serious adverse events were attributed to agenT-797. 

MiNK estimates that approximately 93,000 U.S. patients annually fall within its initial target population of ventilated, pneumonia-associated moderate-to-severe ARDS. Nearly four in ten patients die within 28 days, and no effective FDA-approved drug has been shown to reduce that mortality. 

“I treat ARDS in the ICU, and it is the condition I see most often and can do the least about. We keep patients alive and wait for the immune system to right itself, and too often it does not,” said Terese Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics. “Because agenT-797 comes from inventory, with no matching or conditioning, it can be given in the window when it matters, in any ICU that can thaw and infuse it. That is why we are running the randomized trial.”

ARPA-H Selects agenT-797 to Prove Cell Therapy Can Be Deployed Without a Freezer

In September, MiNK’s agenT-797 was selected as the therapeutic cell system for the Draper-led Reversible Ambient Biostabilization team under ARPA-H’s BioStabilization Systems (BoSS) program. Supported by up to $87 million in program-wide funding over four years for performers; the initiative seeks to move living medicines from cryogenic storage toward room temperature.

Cold chain is the single largest barrier to taking an allogeneic cell therapy beyond specialized centers. MiNK has already delivered cryopreserved agenT-797 to ventilated patients within days of authorization in a conflict zone; removing the freezer would allow a living immune therapy to be stocked like a conventional drug in community hospitals and austere settings. MiNK participates on a fixed-fee basis, complementing its internally funded clinical priorities.

SITC 2026: One Biology from Oncology to Fibrotic Lung Disease

At SITC 2026, MiNK presented new preclinical findings demonstrating the potential of unmodified and engineered iNKT therapies to address two mechanisms that defeat current treatments: tumor resistance and cellular senescence.

In a human organoid model of microsatellite-stable (MSS) colorectal cancer with liver metastases – a setting with no approved immunotherapy – botensilimab and balstilimab alone produced no significant tumor-cell killing. Adding agenT-797 shifted suppressive macrophages toward an antigen-presenting phenotype and unlocked killing, providing mechanistic support for the ongoing investigator-sponsored Phase 2 study at Scripps (NCT07550088).

With Imperial College London, MiNK showed that agenT-797 and MiNK-215, the Company’s FAP-targeted, IL-15-armored CAR-iNKT candidate, act as living senolytics, clearing the therapy-induced senescent cells that chemotherapy and radiation leave behind. MiNK-215 also eliminated FAP-expressing fibroblasts that shield tumors and drive scarring. These same cells fuel treatment resistance in cancer and progression in fibrotic lung disease – including in ARDS survivors whose lungs continue to scar after leaving the ICU – giving MiNK a single thread from oncology to the lung. The Company intends to earn it in sequence: randomized evidence first, then senescence and fibrosis in the clinic.

Externally Funded Clinical Programs Advance Alongside the Randomized Trial

An investigator-sponsored Phase 2 study at Scripps is evaluating agenT-797 with botensilimab and balstilimab in patients with MSS colorectal cancer and liver metastases, building on clinical observations in refractory gastrointestinal cancers, including the disease control rate in PD-1-refractory gastroesophageal cancer reported by Memorial Sloan Kettering investigators at AACR 2026.

At the University of Wisconsin–Madison, an investigator-sponsored Phase 1 study of agenT-797 for graft-versus-host disease (GvHD) prevention, funded by an NIAID STTR award and the Mary Gooze Clinical Trial Award, is moving toward first dosing; the University has informed MiNK that it expects the first patient to be scheduled by December 2026.

Together with the C-Further program in pediatric patients with blood cancers and the ARPA-H BoSS participation, MiNK now has four sources of non-dilutive support advancing its pipeline, allowing the Company to concentrate its own resources on the randomized ARDS readout.

Priorities and Anticipated Milestones into 2027

• Activate U.S. ICU sites and begin U.S. dosing in C-1300-02 before year-end 2026; sustain enrollment
• Meet with FDA before year-end on the adaptive Phase 2b/3 design and discuss supportive regulatory designations
• Report comparative data from the randomized ARDS trial in second half of 2027
• Support first patient dosing in the University of Wisconsin GvHD prevention study
• Extend named-patient access to additional markets where regulations allow
• Advance the ARPA-H BoSS deployability program

Third Quarter 2026 Financial Results

MiNK ended the quarter with $7.5 million in cash and cash equivalents, compared with $8.8 million at June 30, 2026. The Company recognized $0.2 million in pre-commercial product revenue – its first – from agenT-797 supplied through the named-patient access program. Because the program is new, revenue is expected to vary from quarter to quarter based on physician requests and case-by-case regulatory authorizations.

Net loss was $2.6 million, or $0.50 per share, compared with $2.9 million, or $0.65 per share, in the prior-year quarter – a 23% reduction in net loss per share. Cash used in operations decreased to approximately $1.3 million from $2.1 million in the second quarter, the lowest quarterly operating cash use of 2026. For the nine months ended September 30, 2026, net loss was $8.4 million, or $1.69 per share, compared with $9.9 million, or $2.39 per share, in the prior-year period.

General and administrative expense declined 44% to $1.0 million, primarily reflecting lower professional fees and stock compensation expense. Research and development expense increased to $1.8 million from $1.1 million, reflecting randomized Phase 2 activity and the translational analyses presented at scientific meetings during the quarter – spending directed where the randomized trial requires it.

MiNK is prioritizing investment in its randomized clinical program while holding other operating expenses down. The Company is pursuing partnerships and licensing, non-dilutive funding such as its ARPA-H BoSS participation, and potential equity or debt financing to strengthen its balance sheet, with the priority of funding the randomized study through its readout.

Summary Consolidated Financial Information
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
	September 30, 2026			December 31, 2025
Cash and cash equivalents	$	7,471		$	13,360
Other Financial Information
(in thousands)
(unaudited)
	Three months ended September 30,						Nine months ended September 30,
	2026			2025			2026			2025
Pre-commercial product revenue	$	200		$	–		$	200		$	–
Total operating expenses	$	2,837		$	3,184		$	8,936		$	9,937
Net loss	$	2,552		$	2,888		$	8,423		$	9,892
Net loss per share		0.50			0.65			1.69			2.39
Cash used in operations	$	1,276		$	941		$	5,091		$	3,851

Third Quarter 2026 Conference Call and Webcast

MiNK will host a conference call and webcast on Wednesday, November 11, 2026, at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

The live webcast will be accessible at MiNK Therapeutics Investor Relations, with a replay available following the call.

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GvHD, solid tumors, and severe pulmonary inflammation. With a scalable cryopreserved manufacturing process and differentiated biology bridging innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT.

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, anticipated benefits and clinical development of agenT-797, MiNK-215 and other iNKT-based therapies; the design, enrollment, U.S. site activation and dosing, endpoints, proposed adaptive Phase 2b/3 design, FDA engagement and timing of data from C-1300-02; the timing and results of investigator-sponsored studies; potential applications of preclinical findings, including in senescence and fibrotic disease; the possible development of room-temperature stabilization technologies; the scope, expansion and continued operation of named-patient access and any revenue from it; estimates of patient populations and market opportunity; and MiNK’s capital resources, financing plans and anticipated milestones. Early clinical observations and preclinical findings may not be predictive of outcomes in controlled studies or patients. Such statements involve risks and uncertainties, including those detailed in MiNK’s most recent filings with the Securities and Exchange Commission. Actual results may differ materially from those expressed or implied. MiNK cautions investors not to place undue reliance on forward-looking statements, which speak only as of the date of this release, and undertakes no obligation to update them except as required by law.

Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com

Source: MiNK Therapeutics

WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conference:

• Jefferies Global Healthcare Conference, fireside chat on Monday, November 16, 2026 at 2:30 p.m. GMT (9:30 a.m. ET) in London

A live webcast of the fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:

Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker 
media@dyne-tx.com
781-317-1938